Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trans-chalcone
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
trans-chalcone is a natural small molecule flavonoid and the thermodynamically stable isomer of chalcone, found in various plants. It exhibits a broad spectrum of pharmacological activities, including anti-inflammatory, antioxidant, anticancer, and anthelmintic properties. Mechanistically, it acts as a multi-target modulator of several signaling pathways, primarily activating cytoprotective pathways such as Nrf2, SIRT1, and AMPK, while suppressing pro-inflammatory signaling through the inhibition of NF-κB and the NLRP3 inflammasome. Additionally, trans-chalcone has been identified as a pore blocker for large-conductance calcium-activated potassium (BKCa) channels and an antagonist for nociceptive TRP channels (TRPV1 and TRPA1). Research suggests potential therapeutic applications in metabolic diseases like obesity and NAFLD, neurodegenerative conditions such as Parkinson's disease, cardiovascular injuries, and various cancers.
- Other names
- 1,3-diphenyl-2-propen-1-one(E)-chalconeTC
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)AMPK (Adenosine monophosphate–activated protein kinase)SULT (Sulfotransferase family 2A member 1)KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)NF-κBTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on trans-chalcone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trans-chalcone.